Skip to main content
. 2017 Mar 1;4:3. doi: 10.1186/s40734-017-0051-5

Fig. 2.

Fig. 2

Risk differences for adverse events by severity. The risk differences were assessed before and after placebo-adjustment. Negative risk difference favors deutetrabenazine. p-values comparing the risk differences between deutetrabenazine and tetrabenazine were obtained from z-tests. AE = adverse event